Home Endologix

Endologix

First Commercial Implant of Endologix ALTO Abdominal Stent Graft System Done Outside the US by Drs. Andrew Holden and Andrew Hill

Endologix notes they are committed to investing in the highest levels of clinical evidence, by initiating a head-to-head randomized controlled trial where ALTO will be compared to traditional undifferentiated EVAR grafts, with the intent of proving the superiority of ALTO.

Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System

Dr. Matt Thompson, Chief Medical Officer of Endologix Inc. commented, “On September 28, 2017, the FDA issued a letter to health care professionals (“HCPs”) regarding Type III endoleaks after endovascular aneurysm repair (“EVAR”). Read more.

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3/20/19: The awards were approved by the Company’s Compensation Committee, which is comprised of independent Directors, on March 13, 2019, as an inducement material to the Awardees’ entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).

Endologix Reports Positive 1-Year Results from the Ovation® LUCY Study

6/28/18: John Onopchenko, Chief Executive Officer of Endologix, Inc., commented, “We are excited to have completed follow-up on the LUCY study and are pleased that the one-year results suggest, for the first time in a prospective study, that female AAA patients can be treated with EVAR as effectively as men, when using the Ovation System. LUCY’s evidence provides physicians with new information to confidently engage female patients with prospectively derived outcomes previously realized only by male patients.”

Endovascular Aneurysm Sealing with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair in New Study

4/25/18: This retrospective, propensity-weighted study compares long-term survival for the Nellix® EndoVascular Aneurysm Sealing (EVAS) System with traditional endovascular aneurysm repair (EVAR).

Endologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing System

3/5/18: Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS2 IDE Confirmatory Clinical Study of the investigational Nellix® EndoVascular Aneurysm Sealing (EVAS) System by Sajjad M. Hussain, M.D., Chief of the Department of Vascular Surgery at St. Vincent Health and St. Vincent Heart Center of Indiana.

Endologix Reports Positive Clinical Data from the Ovation LUCY

  The LUCY study was led by an advisory board whose members include: Chairperson Jennifer Ash, MD, Christie...

Endologix, Inc. Announces Enrollment of First Patients in ELEVATE IDE Clinical Study

First Patients in ELEVATE IDE Clinical Study Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for...